STABILITY INDICATING REVERSE PHASE ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD DEVELOPMENT AND VALIDATION FOR TAFENOQUINE SUCCINATE IN THE PRESENCE OF DEGRADATION PRODUCTS AND APPLICATION TO GREEN ANALYTICAL CHEMISTRY
{"title":"STABILITY INDICATING REVERSE PHASE ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD DEVELOPMENT AND VALIDATION FOR TAFENOQUINE SUCCINATE IN THE PRESENCE OF DEGRADATION PRODUCTS AND APPLICATION TO GREEN ANALYTICAL CHEMISTRY","authors":"Dr. K. Atchuta Kumar","doi":"10.53555/ecb/2022.11.01.18","DOIUrl":null,"url":null,"abstract":"Tafenoquine Succinate is the succinate salt form of tafenoquine, an orally bioavailable 8-aminoquinoline derivative, with antimalarial activity. In this study, we developed and validated a method to determine Tafenoquine Succinate and its related impurities in pharmaceutical dosage forms using a reverse phase-UPLC technique. All the impurities are separated in the analytical column Waters X bridge C18 (50mm X 4.6 mm, 3.5 µm) using a suitable mobile phase was 0.1% Formic acid and Ethanol in the 55:45 v/v isocratic mode. The flow rate is 0.3 mL/min with the gradient programme the injection volume is 3 µL, detection at 215 nm in UV and the total run time is 10 minutes. The samples were made for forced degradation under hydrolysis, oxidation, thermal and photolytic conditions. The method was validated according to the international conference on Harmonisation (ICH) guidelines and found to be specific, linear, rugged, robust and accurate. The method was linear from LOQ to 150% concentration level for all impurities. The recovery was performed from LOQ to 150% concentration, and the mean recovery was found acceptable. The degradation and validated study results indicate its stable nature. Therefore, this method can be used in pharmaceutical research and development and quality control departments. Green analytical chemistry tools are used to assess the greenness of the method and calculated using GAPI, AGREE and Eco-scale and found excellent green of >75%.","PeriodicalId":11880,"journal":{"name":"European Chemical Bulletin","volume":"46 11","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Chemical Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53555/ecb/2022.11.01.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 0
Abstract
Tafenoquine Succinate is the succinate salt form of tafenoquine, an orally bioavailable 8-aminoquinoline derivative, with antimalarial activity. In this study, we developed and validated a method to determine Tafenoquine Succinate and its related impurities in pharmaceutical dosage forms using a reverse phase-UPLC technique. All the impurities are separated in the analytical column Waters X bridge C18 (50mm X 4.6 mm, 3.5 µm) using a suitable mobile phase was 0.1% Formic acid and Ethanol in the 55:45 v/v isocratic mode. The flow rate is 0.3 mL/min with the gradient programme the injection volume is 3 µL, detection at 215 nm in UV and the total run time is 10 minutes. The samples were made for forced degradation under hydrolysis, oxidation, thermal and photolytic conditions. The method was validated according to the international conference on Harmonisation (ICH) guidelines and found to be specific, linear, rugged, robust and accurate. The method was linear from LOQ to 150% concentration level for all impurities. The recovery was performed from LOQ to 150% concentration, and the mean recovery was found acceptable. The degradation and validated study results indicate its stable nature. Therefore, this method can be used in pharmaceutical research and development and quality control departments. Green analytical chemistry tools are used to assess the greenness of the method and calculated using GAPI, AGREE and Eco-scale and found excellent green of >75%.
琥珀酸他非诺喹是琥珀酸盐形式的他非诺喹,一种口服生物可利用的8-氨基喹啉衍生物,具有抗疟疾活性。在本研究中,我们建立并验证了一种使用反相uplc技术测定药物剂型中琥珀酸他非诺喹及其相关杂质的方法。所有杂质在Waters X bridge C18 (50mm X 4.6 mm, 3.5 µm)分析柱中分离,流动相为0.1%甲酸和乙醇,55:45 v/v等压模式。流速为0.3 mL/min,梯度程序,进样量为3 µL,在215 nm紫外下检测,总运行时间为10分钟。样品在水解、氧化、热和光解条件下进行强制降解。根据国际协调会议(ICH)指南对该方法进行了验证,发现该方法具有特异性、线性性、坚固性、鲁棒性和准确性。该方法在定量限至150%浓度范围内呈线性。从定量限到150%的浓度进行回收,平均回收率可接受。降解和验证研究结果表明其性质稳定。因此,该方法可用于药品研发和质量控制部门。使用绿色分析化学工具评估该方法的绿色度,并使用GAPI, AGREE和Eco-scale进行计算,发现绿色度>75%。